PRIA Logo™
HR7091119th CongressWALLET

Expanding Veterans’ Access to Emerging Treatments Act

Sponsored By: Representative Bergman, Jack [R-MI-1]

In Committee

Summary

This bill would create expanded VA research and access to innovative treatments for veterans. It would set up an investigational research program so veterans with conditions like PTSD, chronic pain, depression, anxiety, traumatic brain injury, or substance use disorders can join clinical trials or be considered for compassionate or extended access to emerging therapies such as MDMA, psilocybin, ketamine, ibogaine, and others.

Show full summary
  • Veterans: Veterans diagnosed with covered conditions could participate in one or more VA clinical trials or seek compassionate or extended access to listed innovative treatments.
  • VA operations and staff: The Secretary would have to name a lead administrator within 60 days and develop the program within 90 days. The VA may run clinical trials and may use amounts otherwise authorized to support them.
  • Oversight and review: The Secretary must report within 1 year on hosting clinics, expected participant numbers, trial findings, and reviews of safety, efficacy, cost, regulatory, and logistical issues. The program must be reviewed at 2 years to decide whether to extend or end it.

Personalized for You

How does this bill affect your finances?

Personalize government policy and PRIA will tell you what this bill means for your household, plus every other piece of legislation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.

Free to download

Bill Overview

Analyzed Economic Effects

1 provisions identified: 1 benefits, 0 costs, 0 mixed.

More experimental treatment access for veterans

This bill would require the Department of Veterans Affairs to start an investigational research program within 90 days to study and, where appropriate, provide veterans access to innovative treatments and emerging therapies for listed conditions. The VA would have to name a lead administrator within 60 days and could run clinical trials that include veterans and create a compassionate or extended access process for care when clinically appropriate. The bill would list example innovative treatments such as MDMA, psilocybin, ketamine, ibogaine, and DMT, and it would require the VA to follow federal laws on investigational products and controlled substances. The VA would report to the House and Senate Veterans' Affairs committees within one year and review the program within two years; funding would be limited to amounts already authorized and available to the VA.

Sponsors & CoSponsors

Sponsor

Bergman, Jack [R-MI-1]

MI • R

Cosponsors

  • Rep. Correa, J. Luis [D-CA-46]

    CA • D

    Sponsored 1/15/2026

  • Rep. Crenshaw, Dan [R-TX-2]

    TX • R

    Sponsored 2/11/2026

  • Rep. Luttrell, Morgan [R-TX-8]

    TX • R

    Sponsored 2/24/2026

Roll Call Votes

No roll call votes available for this bill.

View on Congress.gov
Back to Legislation